There is no harm in clarifying with the company whether their "early 22" means before end of Q1 or before end of April - its a fair question in my view and if you don't ask that question, you don't get IMO. Logically, its a follow-on clarification from HPHQ's question to investor relations, but I probably will ask it in coming days if he confirms he will not. It will end this continuous running dialogue on this BB once and for all. I was expecting results by 31 Jan based on this EARLY 22 statement so we call have different interpretations on this one!
HPHQ. Drop them a quick thank you back and re confirm their definition of " early 22" as it can be interpreted by different people in different ways... in my mind it is pre-expiry of Q1. Is this there understanding too..and will they confirm it??
RE: The misunderstood future of SNG16 Feb 2022 20:07
Global Governments, Companies and around 7bn people on this planet never want to be in this 'hsit' hole virus situation again IMV. The human, social and economic costs are absolutely vast taken together. That's why if phase 3 is good, we are maybe sitting on an emerging £10bn+ therapy.
It's amazing that SNG001 has not AS YET had the same EUA. But it bodes very well for accelerated US progression and market access RIGHT NOW. USA are desperate for a multi-valent or agnostic antiviral approach to covid. Hold those shares tightly and don't under sell on any big rise as this looks amazing if phase 3 readout affirms good efficacy.
No FOMO today = Because we have now all placed our final bets on the roulette table over past weeks with numerous false dawns and now collectively gone big as much as we can, including behind sofa change (investing SNG headlong with confidence) so hence no Friday rise to be seen. Its that simple. We know its a success and we are all going to the big rainbow party very soon.
Totally agree on SP recovery - very oversold and out of favor during Q4 21 (investors got burnt if they sold) -SP recovery was going to happen; this is an very innovative, disruptive R&D business, you cannot value it on near term revenue performance alone - there is massive "silent intellectual property/technology moat" upside in this company in the mid-long term (1-5 years). I'm not ramping, just stating a view on long run where this is going. Historically, ITX had impatient investor delayed adoption issues, but it is very solid IMV for medium - long term growth - far better than a FTSE 100 with low growth (if you are prepared to wait a year or two).
Revenue multiples are only half the story re: ITX SP10 Feb 2022 16:37
Its probably best to value ITX on a prospective revenue multiple (say 2023 Rev) and then add in a "blue sky incremental R&D" value premium from the aggregated IP value collected from R&D investment at cost. The latter is composed of many years of investment in IP much of which has not been written off and is in the pipeline to fuel medium term growth. So ITX appears to be a very cheap platform for SP growth IMV below the placing price. In any case, newsflows of the innovation adds will turn the SP well north over 2022/23+. Its a de-risked technology platform with sticky customers pretty much from here as it gains more commercial traction from cost/eco industrial consumers. Good luck long term investors. DYOR
RE: One Day Closer to Commercialisation for SNG !!08 Feb 2022 20:44
Really good post Trinityman. Totally agree, I've been saying 90% + probability of launch for over a year now given the facts surrounding SNG001, so I'm pleased everyone seems to be aligning on this now. 95% is possible given last few months of activity.
Why is SNG so cheap right now...?08 Feb 2022 09:09
Basically, It's fear of the "unknown voyage" through a scientific breakthrough inflection point, that is SNG001....nobody can predict with any robust degree of accuracy the upside revenue potential for this technology company and one can drive a bus through professional broker estimates of the upside outcomes. Makes for fascinating watching from the side lines awaiting very pivotal news. IMV the current SP equates to almost a complete failure scenario if you think about it, (GBP 370m Mkt Cap), which represents probably only the 10% max of the lower case scenarios that can be generated. So, strap in, enjoy the journey knowing you: (1) are part of a major scientific event in coming days/weeks that may transform the global respiratory ID secondary care sector; (2) change your own life for the better financially. GL DYOR.
Nellie "but sick and tired..... without a shred of concrete evidence." NB. You will NEVER have as much affirmative publicly available evidence and information surrounding a Phase III trial readout PRE READOUT (commercial, scientific, Web site, massive new employee search, ashfield engage, interview positivity, subtle messaging from C suite, polygon large stake share purchases, unmet global market needs, etc shall I go on?) as SNG001 at this time so I doubt your statement holds water.